|
See related Revlimid cap information |
|
|
|
Manufacturer |
Celgene |
|
Distributor |
Hong Kong: Jacobson Medical/Macau: Agencia Lei Va Hong |
|
Contents |
Lenalidomide |
|
Indications |
In combination w/ dexamethasone for the treatment of multiple myeloma patients who have received at least 1 prior therapy.
Click to view Revlimid detailed prescribing infomation |
|
Dosage |
Recommended starting dose: 25 mg once daily on days 1-21 of repeated 28-day cycle w/ dexamethasone 40 mg once daily on days 1-4, 9-12 & 17-20 of each 28-day cycle for the 1st 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on days 1-4 every 28-day cycle.
Click to view Revlimid detailed prescribing infomation |
|
Overdosage |
View Revlimid overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not break/chew/open. Take at the same time each day.). |
|
Contraindications |
Pregnancy & lactation, women of childbearing potential.
Click to view Revlimid detailed prescribing infomation |
|
Special Precautions |
Perform complete blood cell count including WBC, platelet count, Hb & haematorcrit at baseline, wkly for the 1st 8 wk of treatment & mthly thereafter. Renal impairment. Monitor for thromboembolism, signs of bleeding (petechiae & epistaxes), thyroid function, risk of tumour lysis syndrome. Lactose intolerance. May impair ability to drive or operate machinery.
Click to view Revlimid detailed prescribing infomation |
|
Adverse Drug Reactions |
Anaemia, neutropenia, thrombocytopenia, haemorrhagic disorder, insomnia, constipation, diarrhoea, nausea, increase & decrease in wt, rash, muscle cramp, muscle weakness, fatigue, asthenia, peripheral oedema.
View ADR Monitoring Form |
|
Drug Interactions |
Erythropoietic agents, other agents associated w/ increased risk of thrombosis (eg HRT), OC, warfarin, digoxin.
View more drug interactions with Revlimid |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
Storage |
View Revlimid storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Revlimid description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Revlimid mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
L04AX04 - lenalidomide ; Belongs to the class of other immunosuppressants. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Revlimid capsule |
|
Revlimid 5 mg x 21's |
|
Revlimid 10 mg x 21's |
|
Revlimid 15 mg x 21's |
|
Revlimid 25 mg x 21's |
|
|
|
Manufacturer: |
Celgene |
|
Distributor: |
Hong Kong: Jacobson Medical
Macau: Agencia Lei Va Hong |
|
 |
|
|
